BioSpace News Archive

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell- and exosome-based therapeutics for the treatment and prevention of a variety of diseases and disorders, announced today that it has received from Johns Hopkins University a non-exclusive license to intellectual property,

Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported today new data demonstrating regression of an animal model of glioma using exosomes isolated from the Company’s cellular immunotherapy product StemVacs.

Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that it is developing a second clinical candidate, votucalis, which specifically inhibits histamine.

The American College of Radiology Data Science Institute® (ACR® DSI) now offers a catalog of 111 FDA-cleared medical imaging artificial intelligence (AI) algorithms (class II) searchable by company, subspecialty, body area, modality and date cleared.

January 2021 marks the one-year anniversary of HSS Florida, a state-of-the-art facility in West Palm Beach that is part of Hospital for Special Surgery, the world’s leading academic medical center specializing in orthopedics, rheumatology and related disciplines.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced new data further examining Dupixent® (dupilumab) in diseases driven by type 2 inflammation including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP) and eosinophilic esophagitis

HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced the appointment of Leigh MacConell, Ph.D., as Chief Development Officer.

Cerevance, a private drug discovery and development company focused on brain diseases, today announced the appointment of Carrie Ann Cook, a global business development executive with more than 20 years of experience in the pharmaceutical industry, as chief business officer effective February 1, 2021

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that AffyXell Therapeutics (“AffyXell”), the joint venture with Daewoong Pharmaceutical (“Daewoong”), has closed a Series A venture capital investment of $7.3 million to further develop its pipeline of next generation cell and gene therapies.

Cagent Vascular, a developer of serration technology for vessel dilatation in endovascular interventions, announced the results of its PRELUDE-BTK Study at this year’s LINC Symposium on January 29th.